Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Novo Nordisk
Jim Cramer Says Novo Nordisk A/S (NVO) ‘Doesn’t Hold A Candle To Eli Lilly’
We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks discussed by Jim Cramer during the latest lightning round.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earli
Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
Novo, Catalent and FTC
Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings
The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in development of cell and gene therapies.
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent ,
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
12h
Behind the Scenes of Novo Nordisk's Latest Options Trends
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
6d
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
8d
Novo Nordisk: Mounting Challenges
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
15h
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...
1d
Novo Nordisk (0QIU) Gets a Hold from Kepler Capital
In a report released on October 15, David Evans from Kepler Capital maintained a Hold rating on Novo Nordisk (0QIU – Research Report), ...
Cyclingnews.com
3h
Declan Irvine uses 'pioneer' eating skills to manage diabetes and battle Life Time Grand Prix riders at Big Sugar Gravel
Australian Declan Irvine (Team Novo Nordisk) is a bit wary of the 'big' elements at Big Sugar Gravel this Saturday. He's ...
1d
on MSN
Is Novo Nordisk A/S (NVO) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
MM&M
1d
Pipeline Report 2024: See the life-changing therapies showing promise
Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Catalent
India
New York Stock Exchange
Wegovy
Feedback